Analysis of baseline Checkmate-066 specimens showed that for nivolumab-treated patients, relatively high IL-6 was associated with poor OS with an adjusted HR of 1.63 (95% CI 1.04 to 2.55) (univariate HR of 2.43, 95% CI 1.60 to 3.70) and for dacarbazine-treated patients, IL-6 was associated with poor OS....demonstrated that for nivolumab-treated patients, IL-6 was associated with poor OS with an adjusted HR of 3.00 (95% CI 1.80 to 4.99) (univariate HR of 4.34, 95% CI 2.65 to 7.10). For ipilimumab-treated patients, IL-6 was associated with poor OS with an adjusted HR of 3.23 (95% CI 2.01 to 5.17) (univariate HR of 4.93, 95% CI 3.12 to 7.79).